Table 1.
SOC for people with rheumatoid arthritis (RA) | Level of agreement | |
---|---|---|
SOC 1 | People with symptoms of RA should have timely access to a clinician/health professional competent in making a (differential) diagnosis (6 weeks according to European League Against Rheumatism (EULAR) recommendations). | 9.9 |
SOC 2 | People with RA should be given relevant information and education about
|
9.7 |
SOC 3 | People with RA should receive a treatment plan developed individually between them and their clinician at each visit. | 9.2 |
SOC 4 | At the start of any disease-specific treatment, people with RA should be fully educated about the expected benefits and any potential risks, and fully evaluated to assess both clinical status and safety aspects. | 9.6 |
SOC 5 | People with RA should be fully assessed for symptoms, disease activity, damage, comorbidity (including assessment for cardiovascular disease risk factors) and function at diagnosis; these assessments should also be done annually; if disease is not within target, clinical assessment should be done at least 3-monthly (all clinical variables) and possibly more frequently upon significant worsening. | 9.5 |
SOC 6 | People with RA should have rapid access to care when they experience significant worsening of the disease. | 9.7 |
SOC 7 | People with RA should be treated with a disease modifying anti-rheumatic drug (DMARD) as soon as the diagnosis is made. | 9.7 |
SOC 8 | If the target of low disease activity or remission is not achieved using a synthetic DMARD (usually being methotrexate), treatment should be revaluated at least every 3 months. | 9.4 |
SOC 9 | People with RA should be evaluated for pain, and relief of pain associated with RA should be considered. | 9.3 |
SOC 10 | People with RA who have residual joint problems despite state-of-art pharmacological (including intra-articular) and non-pharmacological therapy should be assessed by an orthopaedic surgeon within 3 months from recognition of the refractoriness of the problem, especially if there is joint damage/soft tissue problems that might likely be solved by protective or reconstructive surgery. | 8.7 |
SOC 11 | People with RA should have access to evidence-based pharmacological and non- pharmacological treatment. | 9.7 |
SOC 12 | People with RA should have access to a specialised health professional to receive assessment, advice and training in all matters related to their disease. | 9.4 |
SOC 13 | People with RA should understand the benefit of exercises and physical activity and should be advised to exercise appropriately. | 9.5 |
SOC 14 | People with RA should receive information, advice and training on joint protection and ergonomic principles as well as activity-based methods to enhance functioning in daily life and participation in social roles. They should receive information, advice and training on splints, aids, devices and other products for environmental adaptations. | 9.3 |
SOC 15 | People with RA should receive information and advice about
|
9.3 |
SOC 16 | People with RA who wish to try alternative therapies that some people found symptomatically beneficial, should be informed about the limited evidence. | 8.9 |
These SOC should be a minimum standard for all European countries and should be implemented as soon as possible, but not later than by 2020.
Of the 37 SOC, 21 were excluded because 3 or more experts rated them as not necessary in the third Delphi round. This led to the 16 SOC in the final version. 23 (89%) participants scored the level of agreement (8.7–9.9).